From GlobeNewswire: 2025-05-29 16:10:00

Fulcrum Therapeutics, Inc. announced upcoming presentations at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Association Congress. The presentations will cover preclinical and early clinical results of Pociredir, a novel oral treatment for Sickle Cell Disease. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Initial data in SCD demonstrated proof-of-concept and achieved absolute levels of HbF increases associated with potential overall patient benefit. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD.



Read more at GlobeNewswire: Fulcrum Therapeutics to Present at Upcoming Medical